VOCxi currently has a breath analyser device, BreathEZ, which is designed to detect lung cancer by analysing volatile compounds in the exhaled air. The device is supposed to help in early detection of lung cancer, thereby, improving survival rates for affected patients.
S3 Connected has a digital health platform, Affinal, which is designed to better integrate digital services.
As per the partnership agreement, VOCxi plans to leverage S3’s Affinal platform to create a custom mobile application and a cloud-based solution for BreathEZ. The companies also plan on expanding the usage of BreathEZ to other disease indications.
S3 Connected’s medtech solutions director Bill Betten said: “It is a game-changing product that takes full advantage of our digital health system capabilities, including rapid deployment via our Affinial platform while providing a base for future growth to match VOCxi’s plans.”
Cancer screening and diagnosis is an area of increased development. As per GlobalData analysis, there are more than 500 clinical trials being conducted for devices that aid cancer diagnosis.
